Results 151 to 160 of about 2,259,648 (327)
On the positive solutions of the difference equation x_{n+1}=max{A/x_n^2, Bx_{n-1}/(x_nx_{n-2}^2)}
, 2006 Cengiz Çınar, İbrahim Yalçınkaya
openalex +1 more source
A general method for studying quadratic perturbations of the third-order Lyness difference equation [PDF]
, 2013 Guifeng Deng, Qiuying Lu, Nianzu Liu
openalex +1 more source
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Oscillation criteria for delay difference equations
Electronic Journal of Differential Equations, 2001 This paper is concerned with the oscillation of all solutions of the delay difference equation $$ x_{n+1}-x_n+p_nx_{n-k}=0, quad n=0,1,2,dots $$ where ${p_n}$ is a sequence of nonnegative real numbers and $k$ is a positive integer.
Jianhua Shen, I. P. Stavroulakis
doaj
Rational Recursion Operators for Integrable Differential-Difference Equations. [PDF]
Commun Math Phys, 2019 Carpentier S, Mikhailov AV, Wang JP.
europepmc +1 more source
Molecular Oncology, EarlyView.This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris +10 more
wiley +1 more source
Abstract Differential and Difference Equations
Advances in Difference Equations, 2010 Diagana T +2 more
doaj +2 more sources
Finite Difference Method for Solving Partial Integro-Differential Equations [PDF]
, 2020 Majid Erfanian, Hamed Zeidabadi
openalex +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source